Moderna, Inc. (MRNA)

Market Cap	9.20B
Revenue (ttm)	3.08B
Net Income (ttm)	-2.90B
Shares Out	390.58M
EPS (ttm)	-7.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,157,117
Open	23.92
Previous Close	23.75
Day's Range	23.48 - 24.04
52-Week Range	23.15 - 56.70
Beta	2.01
Analysts	Hold
Price Target	37.15 (+57.68%)
Earnings Date	Nov 6, 2025

About MRNA

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 7, 2018
• Employees: 5,800
• Stock Exchange: NASDAQ
• Ticker Symbol: MRNA
• Website: https://www.modernatx.com

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Analyst Summary

According to 15 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $37.15, which is an increase of 57.68% from the latest price.

Price Target

$37.15

(57.68% upside)

Analyst Consensus: Hold